JPWO2019182109A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019182109A5 JPWO2019182109A5 JP2020507927A JP2020507927A JPWO2019182109A5 JP WO2019182109 A5 JPWO2019182109 A5 JP WO2019182109A5 JP 2020507927 A JP2020507927 A JP 2020507927A JP 2020507927 A JP2020507927 A JP 2020507927A JP WO2019182109 A5 JPWO2019182109 A5 JP WO2019182109A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid complex
- unsubstituted
- substituted
- acid chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 32
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 5
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 4
- 239000005549 deoxyribonucleoside Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 210000001638 cerebellum Anatomy 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical class C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000274 microglia Anatomy 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000002342 ribonucleoside Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000003198 cerebellar cortex Anatomy 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical class C1(=CCCCC1)* 0.000 claims 1
- 210000002451 diencephalon Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 210000001905 globus pallidus Anatomy 0.000 claims 1
- 230000000971 hippocampal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 230000002025 microglial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001577 neostriatum Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000869 occipital lobe Anatomy 0.000 claims 1
- 210000001152 parietal lobe Anatomy 0.000 claims 1
- 210000002975 pon Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- 210000004281 subthalamic nucleus Anatomy 0.000 claims 1
- 210000003478 temporal lobe Anatomy 0.000 claims 1
- 210000001103 thalamus Anatomy 0.000 claims 1
- 210000004885 white matter Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023061429A JP7669602B2 (ja) | 2018-03-22 | 2023-04-05 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| JP2024188699A JP2025063018A (ja) | 2018-03-22 | 2024-10-28 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018055372 | 2018-03-22 | ||
| JP2018055372 | 2018-03-22 | ||
| PCT/JP2019/012077 WO2019182109A1 (ja) | 2018-03-22 | 2019-03-22 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061429A Division JP7669602B2 (ja) | 2018-03-22 | 2023-04-05 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019182109A1 JPWO2019182109A1 (ja) | 2021-03-11 |
| JPWO2019182109A5 true JPWO2019182109A5 (https=) | 2022-03-24 |
| JP7262816B2 JP7262816B2 (ja) | 2023-04-24 |
Family
ID=67986528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507927A Active JP7262816B2 (ja) | 2018-03-22 | 2019-03-22 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| JP2023061429A Active JP7669602B2 (ja) | 2018-03-22 | 2023-04-05 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| JP2024188699A Pending JP2025063018A (ja) | 2018-03-22 | 2024-10-28 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023061429A Active JP7669602B2 (ja) | 2018-03-22 | 2023-04-05 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| JP2024188699A Pending JP2025063018A (ja) | 2018-03-22 | 2024-10-28 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250333736A1 (https=) |
| EP (1) | EP3770257B1 (https=) |
| JP (3) | JP7262816B2 (https=) |
| WO (1) | WO2019182109A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3766972B1 (en) * | 2018-03-14 | 2025-04-23 | Institute of Science Tokyo | Nucleic acid complex |
| JP7262816B2 (ja) * | 2018-03-22 | 2023-04-24 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| US20220370491A1 (en) * | 2019-09-18 | 2022-11-24 | National University Corporation Tokyo Medical And Dental University | Nucleic acid complex |
| WO2022106695A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| WO2023042876A1 (ja) * | 2021-09-15 | 2023-03-23 | 国立大学法人東京医科歯科大学 | ２'－修飾ヌクレオシドを含むヘテロ核酸 |
| CN116789726A (zh) * | 2022-01-28 | 2023-09-22 | 珂阑(上海)医药科技有限公司 | 甾类化合物、其制备方法和应用 |
| JPWO2024071099A1 (https=) | 2022-09-29 | 2024-04-04 | ||
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
| ES2603379T3 (es) | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
| WO2008049085A1 (en) | 2006-10-18 | 2008-04-24 | Isis Pharmaceuticals, Inc. | Antisense compounds |
| AU2012353330B2 (en) * | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
| CA2877985C (en) * | 2012-07-10 | 2020-10-27 | Baseclick Gmbh | Anandamide-modified nucleic acid molecules |
| EP3353306A4 (en) | 2015-09-25 | 2019-06-05 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3517610A4 (en) * | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| JP6562515B2 (ja) | 2016-09-28 | 2019-08-21 | 尾花 敏▲徳▼ | セキュリティシステム |
| US11260134B2 (en) * | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| JP7262816B2 (ja) | 2018-03-22 | 2023-04-24 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
-
2019
- 2019-03-22 JP JP2020507927A patent/JP7262816B2/ja active Active
- 2019-03-22 WO PCT/JP2019/012077 patent/WO2019182109A1/ja not_active Ceased
- 2019-03-22 EP EP19772155.8A patent/EP3770257B1/en active Active
-
2023
- 2023-04-05 JP JP2023061429A patent/JP7669602B2/ja active Active
-
2024
- 2024-10-28 JP JP2024188699A patent/JP2025063018A/ja active Pending
-
2025
- 2025-04-15 US US19/179,469 patent/US20250333736A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019182109A5 (https=) | ||
| US11260134B2 (en) | Double-stranded nucleic acid complex having overhang | |
| JP7669602B2 (ja) | ヘテロ核酸のｂｂｂ通過脂質リガンド | |
| CN100400045C (zh) | 基于核酸的化合物及其使用方法 | |
| JPWO2021178237A5 (https=) | ||
| JP7690979B2 (ja) | 一本鎖オリゴヌクレオチド | |
| JP2021526823A5 (https=) | ||
| RU2015139553A (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP2008545793A5 (https=) | ||
| CN1345242A (zh) | 治疗白血病的方法 | |
| JPWO2021244831A5 (https=) | ||
| JP2001511131A (ja) | 月経前不快障害の処置 | |
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| JP7737667B2 (ja) | 核酸複合体 | |
| WO2004026318A1 (ja) | α-グリコシルセラミドを有効成分とするＣ型肝炎ウイルス抑制剤 | |
| JP5481762B2 (ja) | 脳移行性機能性核酸及びその利用 | |
| JP2004526706A5 (https=) | ||
| KR20080033322A (ko) | 각성을 향상시키는 방법 | |
| JP2006510740A5 (https=) | ||
| WO2024212954A1 (zh) | 抑制lpa基因表达的化合物、药物组合物及其用途 | |
| US20250223591A1 (en) | Syf2 antisense oligonucleotides | |
| CN121517358A (zh) | Cb1配体化合物及其缀合物 | |
| JPWO2023141302A5 (https=) | ||
| Fey et al. | Haematopoietic myeloid growth factors in the treatment of acute myelogenous leukaemia: Players on or off stage? | |
| JPWO2022192536A5 (https=) |